Oxford BioMedica sees lower revenue in 2022 on suspension of Covid-19 vaccine with AstraZeneca
Oxford BioMedica sees lower revenue in 2022 on suspension of Covid-19 vaccine with AstraZeneca

Oxford BioMedica sees lower revenue in 2022 on suspension of Covid-19 vaccine with AstraZeneca

By Sabela Ojea

The Oxford BioMedica PLC said on Wednesday that revenue for 2022 will be below 2021 due to the suspension of a Covid-19 vaccine with AstraZeneca PLC, but that negotiations are continuing on a potential extension of the supply agreement.

The gene and cell therapy group’s revenue for 2021 increased 63% to £ 142.8 million (USD 185.6 million) from GBP 87.7 million for the same period last year.

The London-listed company said operating income before interest, tax, depreciation and amortization increased by GBP28.5 million to GBP35.9 million, while operating profit increased by GBP26.5 million to GBP20.8 million.

The shares at 0752 GMT fell 36.00 pence or 5.6% to 603.00 pence.

Write to Sabela Ojea at sabela.o[email protected]; @sabelaojeaguix

Leave a Reply

Your email address will not be published.